Joshua E. Allen, PhD

Joshua Allen, PhD, joined Chimerix in 2021 as Chief Technology Officer. Dr. Allen discovered the anti-cancer activity of ONC201 and co-invented the imipridone class of compounds. Dr. Allen has continuously advanced the research and development of ONC201 from academic discovery to its registration program, along with the creation and clinical introduction of biologically distinct derivatives. He received his Ph.D. in Biochemistry and Molecular Biophysics from the University of Pennsylvania. Several research publications, patents, grants, and awards reflect his scientific and entrepreneurial efforts in oncology, including recognition on the Forbes 30 under 30 list. Prior to joining Chimerix, Dr. Allen served as Chief Scientific Officer at Oncoceutics. Dr. Allen also serves in advisory roles for disease foundations such as the National Brain Tumor Society and translational medicine programs such as SPARK at Stanford University.

Categorised in:

This post was written by Michelle LaSpaluto